TG Therapeutics, Inc. (TGTX) Stock Price & Analysis

TG Therapeutics, Inc. (TGTX) is trading at USD 52.21, down 1.80% today, as of October 23, 2026 at 15:07 UTC (US market open; quotes may be delayed), according to Nexqual market data.

TGTX last closed at USD 53.16; today's session has ranged USD 51.83–52.74 on volume of 224,050 shares. Market capitalization is $7.99B, with a 52-week range of USD 26.76–59.3 (NCM). Source: Nexqual, retrieved October 23, 2026 at 15:07 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TGTX.md

Key facts (TGTX)

• Last four reported quarters (through Jun 30, 2026): revenue $800M, net income $441M (55.2% margin), free cash flow $17.4M (SEC filings).
• Valuation: P/E 18.1x (avg 139.1x at the last 3 fiscal year-ends), EV/EBITDA 59.5x, net debt $133M.
• Earnings quality: non-operating income -$34.7M vs operating income $136M over the last four quarters; P/E excluding non-operating income ≈16.8x (estimate: non-operating income taxed at the company's 0% effective rate).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $275K; 1 not under a Rule 10b5-1 plan ($275K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.25 on a 1–5 scale) (8 analysts), mean target USD 69.71 (range 21–86).
• Total return with dividends: 1Y +55.9% vs S&P 500 +14.8%; 5Y +67.2% vs S&P 500 +77.5%.
• Next earnings: 2026-11-02, EPS estimate USD 0.26, revenue estimate $245M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TGTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TGTX)

P/E 18.1x · P/E ex non-operating (est.) ≈16.8x · P/S 10.0x · EV/EBITDA 59.5x · EV/Sales 10.2x · P/FCF 459.7x · P/B 13.2x · FCF yield 0.22% · Earnings yield 5.52% · Net debt $133M · EV $8.12B

P/E at fiscal year-ends: Dec 2025 10.8x, Dec 2024 206.4x, Dec 2023 200.2x.

Insider sales (SEC Form 4, open-market, last ~7 months) (TGTX)

0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (TGTX)

Consensus Buy (mean 2.25 on a 1–5 scale), 8 analysts; mean target USD 69.71 (low 21, high 86).

Rating changes, last 120 days:

Total return (dividends reinvested) (TGTX)

TGTX revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

TGTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 27, 2026.

Companies that name TGTX in their SEC reports

TGTX customer concentration

In the period ended Jun 30, 2026, 4 direct customers each accounted for at least 10% (40%, 29%, 19%, 12%) of revenue, per the company's 10-Q filed Aug 5, 2026. The company does not name them.

TGTX company outlook (results filed Aug 3, 2026)

• “(NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance.”
• “BRIUMVI delivered another outstanding commercial quarter, exceeding our expectations once again and putting us on track to exit 2026 at an approximately $1 billion annualized U.S.”

Quoted word-for-word from the SEC 8-K results press release.

TGTX analyst estimates and revisions

TGTX options: expected move

Options price a move of about ±15.6% (±$8.23) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±11.3% on average.

30-day implied volatility 62.2% vs 35.7% realized over the last 30 trading days. Put/call ratio (volume) 0.39. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 15:07 UTC)

Technical Analysis (TGTX)

Nexqual's technical model rates TGTX "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 15:07 UTC.

Analyst Ratings (TGTX)

Wall Street analysts rate TGTX "Buy" based on 8 analysts, with a mean price target of USD 69.71 (range USD 21–86), per Nexqual as of October 23, 2026 at 15:07 UTC.

Earnings (TGTX)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Financials & Fundamentals (TGTX)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Financial Health Score (TGTX)

Nexqual rates TG Therapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 15:07 UTC.

Ownership (TGTX)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Leadership (TGTX)

TG Therapeutics, Inc. is led by Michael S. Weiss Esq., Chairman, CEO & President, per Nexqual as of October 23, 2026 at 15:07 UTC.

Major Backers & Investors (TGTX)

Notable institutional backers of TG Therapeutics, Inc. include Shaw D.E. & Co., Inc., Soleus Capital Management, L.P., Price (T.Rowe) Associates Inc, according to Nexqual as of October 23, 2026 at 15:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

From TG Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• To this end, we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees and consultants.
• Before marketing in the U.S., any drug that we develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory review and approval process implemented by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and, in the case of biologics, the Public Health Service Act.
• Our approach is enabled by our clinical development platform which includes an internal team with a deep understanding of B-cell mediated diseases and significant experience successfully obtaining FDA approval for innovative treatments for these complex diseases.
• Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.

Partnerships

• In August 2023, we entered into a Commercialization Agreement with Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, for the ex-U.S. commercialization of BRIUMVI.
• Pursuant to our license agreement with Precision, we have an exclusive license to develop and commercialize Precision's azer-cel for the treatment of autoimmune and other non-oncology diseases and conditions as well as a non-exclusive license to manufacture azer-cel.

Legal & Regulatory Risks (Item 1A, quoted)

• We also could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the DSMB for such trial or by the FDA or other regulatory authorities.
• Our product or product candidates may cause undesirable side effects or adverse events that could delay or prevent their regulatory approval or impact their availability and commercial potential after approval.
• Any products or product candidates we may advance through clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals.
• We may seek Breakthrough Therapy or Fast Track designation for some of our drug candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:07 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt